These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 23042862)

  • 1. Biomedicine. Pharma firms push for sharing of cancer trial data.
    Bhattacharjee Y
    Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
    [No Abstract]   [Full Text] [Related]  

  • 2. Project data sphere to make cancer clinical trial data publicly available.
    Hede K
    J Natl Cancer Inst; 2013 Aug; 105(16):1159-60. PubMed ID: 23904505
    [No Abstract]   [Full Text] [Related]  

  • 3. Discontinued drugs in 2010: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 5. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
    Perakslis ED; Van Dam J; Szalma S
    Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
    [No Abstract]   [Full Text] [Related]  

  • 7. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traditional drug-discovery model ripe for reform.
    Cressey D
    Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
    [No Abstract]   [Full Text] [Related]  

  • 9. A bitter pill.
    Nat Chem; 2010 May; 2(5):337. PubMed ID: 20414223
    [No Abstract]   [Full Text] [Related]  

  • 10. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 11. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buy buy bispecific antibodies.
    Holmes D
    Nat Rev Drug Discov; 2011 Oct; 10(11):798-800. PubMed ID: 22037028
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicine. Can intellectual property save drug development?
    FitzGerald GA
    Science; 2012 Oct; 338(6106):483-4. PubMed ID: 23112323
    [No Abstract]   [Full Text] [Related]  

  • 14. To make better therapeutics, companies strive to increase the content of results and get them faster.
    Szpir M
    Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical setbacks for toll-like receptor 9 agonists in cancer.
    Schmidt C
    Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
    [No Abstract]   [Full Text] [Related]  

  • 16. India's drug tests.
    Padma TV
    Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
    [No Abstract]   [Full Text] [Related]  

  • 17. [Towards bioproduction of anticancer drugs by yeast].
    Courdavault V; Papon N; Clastre M
    Med Sci (Paris); 2019 May; 35(5):417-419. PubMed ID: 31115322
    [No Abstract]   [Full Text] [Related]  

  • 18. Precompetitive activity to address the biological data needs of drug discovery.
    Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
    Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
    [No Abstract]   [Full Text] [Related]  

  • 19. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 20. Algeta and Ablynx collaborate to discover and develop targeted cancer therapies.
    King G
    Future Med Chem; 2013 Feb; 5(2):123. PubMed ID: 23476969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.